Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
Si‐Ho Kim, Yu Mi Wi, Su Yeon Yun, Jeong Seon Ryu, Jung Min Shin, Eun Hui Lee, Kyung Hwa Seo, Sung Hee Lee, Kyong Ran Peck
Abstract
< 0.001 for all). Young HCWs reported more AEs with ChAdOx1 nCoV-19 than with BNT162b2. No incidences of anaphylaxis were observed. Only one serious AE required hospitalization for serious vomiting, and completely recovered. In conclusion, reported AEs were more common in recipients with ChAdOx1 nCoV-19 than in those with BNT162b2. However, most of the reported AEs were mild to moderate in severity. Sufficient explanation and preparation for expected AEs required to promote widespread vaccination.
Topics & Concepts
MedicineVaccinationCoronavirus disease 2019 (COVID-19)Adverse effectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)myalgia2019-20 coronavirus outbreakHealth careInternal medicineVomitingVirologyDiseaseOutbreakInfectious disease (medical specialty)Economic growthEconomicsSARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisVaccine Coverage and Hesitancy